Literature DB >> 31452060

Common genetic variations of deiodinase genes and prognosis of brain tumor patients.

Adomas Bunevicius1,2,3, Edward R Laws4,5, Ausra Saudargiene6, Arimantas Tamasauskas6, Giorgio Iervasi7, Vytenis Deltuva6, Timothy R Smith4,5, Robertas Bunevicius8.   

Abstract

BACKGROUND: Thyroid hormone (TH) metabolism can have prognostic significance in brain tumors. We studied the association of common variations in three deiodinase gene single-nucleotide polymorphisms (SNPs) with circulating TH concentrations and prognosis of brain tumor patients.
METHODS: Patients admitted for glioma and meningioma surgery between January, 2010 and September, 2011 were evaluated for functional status (Barthel Index or BI) and circulating free tri-iodothyronine (FT3), free thyroxine (FT4), and thyroid-stimulating hormone (TSH) concentrations. Ten common SNPs in the DIO1 gene; five SNPs in the DIO2 gene; and one SNP in the DIO3 gene were genotyped. Follow-up continued until November, 2017.
RESULTS: In glioblastoma patients, the DIO1 SNP rs2235544 CC genotype was associated with significantly lower risk of death at 2 years when compared to AA + CA genotypes after adjusting for patient gender, age, pre-operative functional status, adjuvant therapy, and extent of resection (HR = 0.34, 95% CI: 0.13-0.84, p = 0.019). The TT genotype vs. CC + TC genotypes of the DI02 SNP rs12885300 was associated with increased mortality risk after adjusting for patient gender, age, pre-operative functional status, adjuvant therapy, extent of resection, and FT3/FT4 (HR = 3.13, 95% CI: 1.20-8.16, p < 0.019). The C-allele of the DI01 SNP rs2235544 was related to increased circulating free T3/ free T4 ratio in glioma and meningioma patients, indicating greater T4 to T3 conversion.
CONCLUSIONS: SNPs of DIO1 gene (rs2235544) and DIO2 gene (rs12885300) have independent prognostic significance in glioblastoma patients. The C-allele of the DIO1 (rs2235544) is associated with greater T4 to T3 conversion.

Entities:  

Keywords:  Deiodinase; Glioblastoma; Glioma; Survival

Mesh:

Substances:

Year:  2019        PMID: 31452060     DOI: 10.1007/s12020-019-02016-6

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  3 in total

1.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX.

Authors:  F I MAHONEY; D W BARTHEL
Journal:  Md State Med J       Date:  1965-02

2.  Cell-type-dependent thyroid hormone effects on glioma tumor cell lines.

Authors:  Alexandros Liappas; Liappas Alexandros; Iordanis Mourouzis; Mourouzis Iordanis; Athanasios Zisakis; Zisakis Athanasios; Konstantinos Economou; Economou Konstantinos; Robert-William Lea; Lea Robert-William; Constantinos Pantos; Pantos Constantinos
Journal:  J Thyroid Res       Date:  2011-12-21

3.  Preoperative low tri-iodothyronine concentration is associated with worse health status and shorter five year survival of primary brain tumor patients.

Authors:  Adomas Bunevicius; Vytenis Pranas Deltuva; Sarunas Tamasauskas; Timothy Smith; Edward R Laws; Robertas Bunevicius; Giorgio Iervasi; Arimantas Tamasauskas
Journal:  Oncotarget       Date:  2017-01-31
  3 in total
  3 in total

1.  Targeting the right population for T3 + T4 combined therapy: where are we now and where to next?

Authors:  Tommaso Porcelli; Domenico Salvatore
Journal:  Endocrine       Date:  2020-06-22       Impact factor: 3.633

Review 2.  Deiodinases and Cancer.

Authors:  Annarita Nappi; Maria Angela De Stefano; Monica Dentice; Domenico Salvatore
Journal:  Endocrinology       Date:  2021-04-01       Impact factor: 4.736

3.  TERT Alterations Predict Tumor Progression in De Novo High-Grade Meningiomas Following Adjuvant Radiotherapy.

Authors:  Jiaojiao Deng; Shuchen Sun; Jiawei Chen; Daijun Wang; Haixia Cheng; Hong Chen; Qing Xie; Lingyang Hua; Ye Gong
Journal:  Front Oncol       Date:  2021-10-29       Impact factor: 6.244

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.